Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Sep 2025 value amounting to $13.2 million.

  • Catalyst Pharmaceuticals' Change in Accured Expenses fell 33.95% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year decrease of 47.58%. This contributed to the annual value of $53.8 million for FY2024, which is 828.41% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Change in Accured Expenses of $13.2 million as of Q3 2025, which was up 60.21% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Accured Expenses registered a high of $20.0 million during Q3 2024, and its lowest value of -$7.0 million during Q1 2021.
  • In the last 3 years, Catalyst Pharmaceuticals' Change in Accured Expenses had a median value of $8.3 million in 2025 and averaged $7.1 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Change in Accured Expenses tumbled by 316.77% in 2023 and then surged by 449.88% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Change in Accured Expenses stood at $6.4 million in 2021, then skyrocketed by 78.78% to $11.5 million in 2022, then decreased by 28.82% to $8.2 million in 2023, then rose by 8.67% to $8.9 million in 2024, then plummeted by 33.95% to $13.2 million in 2025.
  • Its Change in Accured Expenses stands at $13.2 million for Q3 2025, versus $8.3 million for Q2 2025 and -$2.6 million for Q1 2025.